A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Phase 1 Terminated 22 enrolled Celgene Corporation AbbVie · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

CC-90009-AML-002 is an exploratory Phase 1b, open-label, multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in participants with acute myeloid leukemia (AML).

Timeline

Start: 2020-08-05
Primary completion: 2023-10-25
Completion: 2024-04-05

Outcome

Outcome not reported

Stopped (Business): “Business objectives have changed.”

Publications

Surka C, Jin L, Mbong N, Lu CC, Jang IS, Rychak E, Mendy D, Clayton T, Tindall E, Hsu C, Fontanillo C, Tran E, Contreras A, Ng SWK, Matyskiela M, Wang K, Chamberlain P, Cathers B, Carmichael J, Hansen J, Wang JCY, Minden MD, Fan J, Pierce DW, Pourdehnad M, Rolfe M, Lopez-Girona A, Dick JE, Lu G. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood. 2021 Feb 4;137(5):661-677. doi: 10.1182/blood.2020008676.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azacitidine	Other / unclassified	—	Intravenous
Subject	CC-90009	Other / unclassified	—	Intravenous
Subject	Gilteritinib	Small molecule	—	Oral
Subject	Venetoclax	Small molecule	—	Oral